NCT05417984

Brief Summary

Patients with isolated medial compartment arthritis of the knee are commonly treated with unicompartmental knee arthroplasty (UKA). In contrast with total knee arthroplasty (TKA), UKA shows a higher revision rate, which might be due to implant malpositioning and postoperative malalignment of the lower limb and incorrect soft tissue balancing. Nowadays, robotic-assisted UKA is used which improves accurate positioning, optimizes soft-tissue balancing and optimizes radiographic alignment of the implant. The potential benefit could be that this better alignment and positioning results in improved functional outcome and long-term survivorship. As there is a lack in long-term results, more research is needed to the long-term results of robotic-assisted UKA. As long-term results are related to early migration of the implant, investigating the early migration will have additional value to predict the long-term results of robotic-assisted UKA. In this study, we will investigate the early migration of a unicompartmental knee implant (Restoris MultiCompartmental Knee Implant System (Restoris MCK)) used in robotic-assisted UKA using model-based roentgen stereogrammetric analysis (mRSA) and we will relate the migration of this implant to the long-term results of the implant. The primary objective is to assess the fixation and migration patterns of the Restoris MutliCompartmental Knee Implant System (Stryker) in vivo, using mRSA, over 5 years. Secondary objectives are to analyse survival, clinical scores and radiographic aspects of the Restoris MultiCompartmental Knee Implant System (Stryker) and to relate these to the migration patterns over 5 years. A prospective cohort study with 5 years follow-up, in which 33 patients will be enrolled. Patients 18 years or older who require a unicompartmental knee prosthesis as a result of moderately disabling joint disease of the knee will be included. During surgery tantalum markers will be placed to be able to perform mRSA. Patients will be evaluated preoperatively, at 6 weeks, 6 months, 1 year, 2 years and 5 years. The main study parameters are the migration of the Restoris MCK of both the tibial and femoral component presented in x-, y- and z-direction. Secondary study parameters are the alignment, survival of the Restoris MCK, clinical scores and radiographic aspects (both x-ray and CT scan).

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
37mo left

Started Jun 2022

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Jun 2022Jun 2029

First Submitted

Initial submission to the registry

May 30, 2022

Completed
2 days until next milestone

Study Start

First participant enrolled

June 1, 2022

Completed
13 days until next milestone

First Posted

Study publicly available on registry

June 14, 2022

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2029

Last Updated

June 14, 2022

Status Verified

May 1, 2022

Enrollment Period

7 years

First QC Date

May 30, 2022

Last Update Submit

June 10, 2022

Conditions

Keywords

Unicompartimental knee arthroplastyRobotic-assisted knee replacementMigration

Outcome Measures

Primary Outcomes (2)

  • Translation along x-, y- and z-axes

    The translation of both the tibial and femoral component is expressed in mm and is given in 3 directions, namely along the x-, y- and z-axes.

    5 years after surgery at the following time points: 6 weeks, 6 months, 1 year, 2 years and 5 years postoperative.

  • Rotation about x-, y- and z-axes

    The rotation of both the tibial and femoral component is expressed in degrees and is given in 3 directions, namely about the x-, y- and z-axes.

    5 years after surgery at the following time points: 6 weeks, 6 months, 1 year, 2 years and 5 years postoperative.

Secondary Outcomes (10)

  • Survival

    5 years after surgery

  • NRS Pain

    5 years after surgery at the following time points: preoperative, 6 weeks, 6 months, 1 year, 2 years and 5 years postoperative.

  • KSS

    5 years after surgery at the following time points: preoperative, 6 weeks, 6 months, 1 year, 2 years and 5 years postoperative.

  • ROM

    5 years after surgery at the following time points: preoperative, 6 weeks, 6 months, 1 year, 2 years and 5 years postoperative.

  • KOOS-PS

    5 years after surgery at the following time points: preoperative, 6 weeks, 6 months, 1 year, 2 years and 5 years postoperative.

  • +5 more secondary outcomes

Interventions

During this study the Restoris MCK will be placed using robotic-assisted surgery. At the time of surgery tantalum markers will be placed in the tibia and femur. With these markers migration of the prothesis can be measured over time using RSA radiographs.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The population will consist of all patients who present at the Reinier Haga Orthopedisch Centrum, require unicompartmental knee prosthesis (UKP) and satisfy the inclusion and exclusion criteria as stated below.

You may qualify if:

  • Indication for medial unicompartmental knee replacement as described in the manufacturer's guideline, namely as a result of moderately disabling joint disease of the knee resulting from:
  • Painful osteo- or post-traumatic arthritis
  • As an alternative to tibial osteotomy
  • Age \> 18 years
  • Patient qualified for UKP based on physical exam and medical history
  • Patient is able to speak and write Dutch
  • Patient is willing to participate
  • Patient is able and willing to provide written informed consent

You may not qualify if:

  • Contraindication as described by the manufacturer:
  • Inflammatory arthritis or tricompartmental disease
  • Greater than 10 degrees of hyperextension
  • Greater than 10 degrees of varus or valgus deformity
  • Presence of infection (including history of infection), acute or chronic, local or systematic
  • Either mental or neuromuscular disorders that do not allow control of the knee joint
  • Insufficient bone stock to allow appropriate insertion and fixation of the prosthesis
  • Insufficient soft tissue integrity to provide adequate stability
  • Insufficient articulation of the hip joint
  • Metal in the operative or non-operative leg which lead to the creation of accuracy-reducing artefacts in the CT scan
  • Insufficient bone quality to provide adequate stability
  • Loss of ligament structures to prevent creation of an ideal intra-operative plan
  • Patients has a known or suspected sensitivity or allergy to one or more of the implant materials
  • Revision UKP surgery of the same compartment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2022

First Posted

June 14, 2022

Study Start

June 1, 2022

Primary Completion (Estimated)

June 1, 2029

Study Completion (Estimated)

June 1, 2029

Last Updated

June 14, 2022

Record last verified: 2022-05